Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Multiple Myeloma 81Neoplasms, Plasma Cell 27Neoplasms 13Brain Neoplasms 11Prostatic Neoplasms 10Central Nervous System Neoplasms 10Melanoma 9Leukemia 9Glioblastoma 8Gliosarcoma 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Hepatocellular 6Recurrence 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Immunoglobulin Light-chain Amyloidosis 4Carcinoma, Renal Cell 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × Thalidomide × Clear all
NCT00165230 2009-04-28

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡